Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Acura Pharmaceuticals and King Pharmaceuticals Provide Update on Acurox® NDA
Acura Pharmaceuticals Reports Second Quarter 2009 Financial Results
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Acura Pharmaceuticals Receives Preliminary Review Letter from FDA Regarding Acurox(r)
King Pharmaceuticals Reports First-Quarter 2009 Financial Results
Acura Pharmaceuticals Reports First Quarter 2009 Financial Results
Acura Pharmaceuticals, Inc. Names Garth Boehm, Ph.D. VP of Modified Release Dosage Form Development
Acura Pharmaceuticals to Present At Cowen and Company Health Care Conference
Premier Research Announces Milestone New Drug Application
Acurox(r) Tablets New Drug Application Accepted for Filing With a Priority Review Classification
Acura Pharmaceuticals Reports Year-End and Fourth Quarter 2008 Financial Results
Acura Pharmaceuticals, Inc. Names Albert W. Brzeczko, Ph.D. VP, Technical Affairs
New Drug Application Submitted For Acurox(r) Tablets
King Pharmaceuticals Exercises Option to License Fourth Opioid Product From Acura Pharmaceuticals
Acura Pharmaceuticals, Inc. Reports Third Quarter 2008 Financial Results
Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of Key Clinical Study Assessing Abuse Liability
Acura Pharmaceuticals, Inc. to Present At Natixis Bleichroeder Hidden Gems Conference
Acura Pharmaceuticals, Inc. Announces Return of President and CEO From Medical Leave
Acura Pharmaceuticals, Inc. Reports Second Quarter 2008 Financial Results
Acura Pharmaceuticals, Inc. Announces Action Regarding Notice of Allowance Received for Second Aversion Technology Patent
Acura Pharmaceuticals, Inc. Receives $5.0 Million Milestone Payment
Acura Pharmaceuticals, Inc. Added to the Russell 3000 Index and the Russell Microcap Index
Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study
Acura Pharmaceuticals, Inc. Announces Notice of Allowance for Second Aversion Technology Patent
Acura Pharmaceuticals, Inc. Announces Active IND for Second Opioid Analgesic Product Candidate Using Aversion Technology
King Pharmaceuticals Exercises Option to License Third Opioid Product Utilizing Acura's AVERSION Technology
Acura Pharmaceuticals, Inc. Reports First Quarter 2008 Financial Results
King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal Phase III Clinical Trial Evaluating ACUROX(TM)
King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal Phase III Clinical Trial Evaluating ACUROX
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
